Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations.
Adolescent
Adult
Antiviral Agents
/ administration & dosage
Carbamates
/ administration & dosage
Child
Dose-Response Relationship, Drug
Egypt
Female
Hepatitis C, Chronic
/ drug therapy
Humans
Imidazoles
/ administration & dosage
Male
Pyrrolidines
/ administration & dosage
Sofosbuvir
/ administration & dosage
Treatment Outcome
Valine
/ administration & dosage
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
30
7
2021
medline:
19
1
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Sofosbuvir (SOF)/daclatasvir (DCV) is the direct-acting antiviral regimen of choice in many low- and middle-income countries for curative treatment of chronic hepatitis C virus (HCV) infection in adults, but data on the use of DCV in children are lacking. We performed a population pharmacokinetic (PK) analysis to predict DCV exposure in children treated with available adult formulations. DCV concentration data from HCV-infected adolescents receiving SOF/DCV [400/60 mg, once daily (OD)] who participated in a PK study in Egypt were used for model development. PK parameters were estimated using a population approach. Monte Carlo simulations were run for virtual children weighing 10 to <35 kg receiving 60 or 30 mg OD, and DCV exposures were compared with adults ranges. Seventeen HCV-infected adolescents (13 males) provided 151 DCV concentrations. Median (range) age was 14 (11-18) years and weight 50 (32-63) kg. In these adolescents receiving 60 mg DCV, median (interquartile range) DCV area under the concentration time curve 0 to 24 hours, maximum concentrations, and minimum concentrations were 11,130 (8140-14,690) ng·h/mL, 1030 (790-1220) ng/mL and 130 (110-220) ng/mL, respectively, compared with 10,343 (7661-14,095) ng·h/mL, 1132 (876-1518) ng/mL and 110 (55.7-192) ng/mL predicted in children 10 to <35 kg receiving 30 mg. The proportion of children with DCV exposures above the adult range rapidly increased for children <30 kg using 60 mg OD, similarly for children 10-14 kg using 30 mg. DCV 30 mg OD was predicted to achieve effective and safe exposures in children 14 to <35 kg, perhaps down to 10 kg. These results should be validated clinically. Low-cost available adult DCV formulations together with approved pediatric doses of SOF would expand global access to HCV treatment for children.
Sections du résumé
BACKGROUND
BACKGROUND
Sofosbuvir (SOF)/daclatasvir (DCV) is the direct-acting antiviral regimen of choice in many low- and middle-income countries for curative treatment of chronic hepatitis C virus (HCV) infection in adults, but data on the use of DCV in children are lacking. We performed a population pharmacokinetic (PK) analysis to predict DCV exposure in children treated with available adult formulations.
METHODS
METHODS
DCV concentration data from HCV-infected adolescents receiving SOF/DCV [400/60 mg, once daily (OD)] who participated in a PK study in Egypt were used for model development. PK parameters were estimated using a population approach. Monte Carlo simulations were run for virtual children weighing 10 to <35 kg receiving 60 or 30 mg OD, and DCV exposures were compared with adults ranges.
RESULTS
RESULTS
Seventeen HCV-infected adolescents (13 males) provided 151 DCV concentrations. Median (range) age was 14 (11-18) years and weight 50 (32-63) kg. In these adolescents receiving 60 mg DCV, median (interquartile range) DCV area under the concentration time curve 0 to 24 hours, maximum concentrations, and minimum concentrations were 11,130 (8140-14,690) ng·h/mL, 1030 (790-1220) ng/mL and 130 (110-220) ng/mL, respectively, compared with 10,343 (7661-14,095) ng·h/mL, 1132 (876-1518) ng/mL and 110 (55.7-192) ng/mL predicted in children 10 to <35 kg receiving 30 mg. The proportion of children with DCV exposures above the adult range rapidly increased for children <30 kg using 60 mg OD, similarly for children 10-14 kg using 30 mg.
CONCLUSIONS
CONCLUSIONS
DCV 30 mg OD was predicted to achieve effective and safe exposures in children 14 to <35 kg, perhaps down to 10 kg. These results should be validated clinically. Low-cost available adult DCV formulations together with approved pediatric doses of SOF would expand global access to HCV treatment for children.
Identifiants
pubmed: 34321444
doi: 10.1097/INF.0000000000003282
pii: 00006454-900000000-95720
doi:
Substances chimiques
Antiviral Agents
0
Carbamates
0
Imidazoles
0
Pyrrolidines
0
Valine
HG18B9YRS7
daclatasvir
LI2427F9CI
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1086Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016–2021: actions for impact. 2021. Available at: https://www.who.int/publications/i/item/9789240027077. Accessed April 7, 2021.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477–487.
Malik F, Bailey H, Chan P, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. JHEP Rep. 2021;3:100227.
Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5:374–392.
Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:175–181.
Indolfi G, Fischler B, Gonzalez-Peralta RP, et al.; Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN). Comparison of recommendations for treatment of chronic hepatitis C virus infection in children and adolescents: a position paper of the federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2020;70:711–717.
Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology. 2008;47:836–843.
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [Internet]. Geneva. 2018. Available at: https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf. Accessed March 4, 2021.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series(). J Hepatol. 2020;73:1170–1218.
Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the study of liver diseases-Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71:686–721.
US Food & Drug Administration. FDA approves new treatment for pediatric patients with any strain of hepatitis C. March 19, 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-any-strain-hepatitis-c. Accessed March 4, 2021.
Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2020;71:31–43.
Murray KF, Balistreri WF, Bansal S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. Hepatology. 2018;68:2158–2166.
Jonas M, Romero R, Sokal E, et al. Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection (IDDF2020-ABS-0059). Gut. 2020;69(Suppl 2):A1–A95.
Serranti D, Dodi I, Nicastro E, et al. Shortened 8-week course of sofosbuvir/ledipasvir therapy in adolescents with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2019;69:595–598.
El-Shabrawi MH, Abdo AM, El-Khayat HR, et al. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;66:425–427.
World Health Organization. Accelerating access to hepatitis C diagnostics and treatment Overcoming barriers in low and middle-income countries. Global progress report 2020. Available at: https://www.who.int/publications/i/item/9789240019003. Accessed April 2, 2021.
Indolfi G, Giometto S, Serranti D, et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52:1125–1133.
Al-Nahari MM, Abbassi MM, Ebeid FS, et al. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. Antivir Ther. 2020;25:101–110.
Hézode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809–1816.
Chan P, Li H, Zhu L, et al. Population pharmacokinetic analysis of daclatasvir in subjects with chronic hepatitis C virus infection. Clin Pharmacokinet. 2017;56:1173–1183.
Lacombe K, Fontaine H, Dhiver C, et al. Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access cohort. J Acquir Immune Defic Syndr. 2017;75:97–107.
Antonini TM, Coilly A, Rossignol E, et al.; ANRS C023 CUPILT study group. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation. 2018;102:119–126.
Rockstroh JK, Ingiliz P, Petersen J, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther. 2017;22:225–236.
Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42:258–272.
Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat. 2019;26:263–270.
Yakoot M, El-Shabrawi MH, AbdElgawad MM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;67:86–89.
Indolfi G, Guido M, Azzari C, et al. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther. 2015;13:1225–1235.
González-Peralta RP, Langham MR Jr, Andres JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48:630–635.
El-Sayed MH, Indolfi G. Hepatitis C virus treatment in children: a challenge for hepatitis C virus elimination. Semin Liver Dis. 2020;40:213–224.
Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019;70:371–378.
Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol. 2008;23:226–230.
The World Bank. Population ages 0-14 (% of total population). Available at: https://data.worldbank.org/indicator/SP.POP.0014.TO.ZS. Accessed March 10, 2021.
Osawa M, Ueno T, Ishikawa H, et al. Population pharmacokinetic analysis for daclatasvir and asunaprevir in japanese subjects with chronic hepatitis C virus infection. J Clin Pharmacol. 2018;58:1468–1478.
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–332.